Matthew Pabis, MD
Family Medicine · New York, NYNPI 1376981589
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,525 of the $221,961 with a category attached, or 74.6%. Alkermes, Inc. accounts for 61.0% of it on its own, with 49 other manufacturers making up the rest. 2025 is the largest year on record at $66,656, more than ten times the $2,903 reported in 2019. Among family medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,160 payments — averaging $191.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$135K
- Axsome Therapeutics, Inc.$44K
- Gilead$21K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
- AbbVie$3K
- Viiv Healthcare Company$2K
- plus $11K from 44 others
What the payments were for
- Consulting fees$19,9709%
- Speaking & faculty fees$165,52575%
- Travel & lodging$6,6473%
- Food & beverage$29,74713%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$221,961 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 100 | $405,814 |
| OzempicSemaglutide | 140 | $159,130 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $118,003 |
| RukobiaFostemsavir Tromethamine | 13 | $108,670 |
| JanuviaSitagliptin Phosphate | 69 | $61,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $59,675 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 12 | $56,617 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $38,073 |
| AuvelityDextromethorphan Hbr/Bupropion | 40 | $37,343 |
| RexultiBrexpiprazole | 20 | $36,889 |
| AristadaAripiprazole Lauroxil | 12 | $33,033 |
| IsentressRaltegravir Potassium | 16 | $29,627 |
| TivicayDolutegravir Sodium | 13 | $29,503 |
| FarxigaDapagliflozin Propanediol | 25 | $25,736 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 88 | $25,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Xarelto | $687 | $413,630114 claims |
| Viiv Healthcare CompanyRukobia, Dovato, Tivicay | $1,953 | $176,24639 claims |
| GileadBiktarvy | $21,409 | $118,00326 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $539 | $66,32886 claims |
| Alkermes, Inc.Aristada, Vivitrol | $135,484 | $54,38226 claims |
| Axsome Therapeutics, Inc.Auvelity | $44,278 | $37,34340 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $580 | $36,88920 claims |
| Lilly USA, LLCMounjaro, Trulicity | $272 | $32,36233 claims |
| AstraZenecaFarxiga | $237 | $25,73625 claims |
| Redhill Biopharma Inc.Movantik | $19 | $17,77432 claims |
| AbbVieLinzess | $2,501 | $17,20114 claims |
| PfizerEliquis | $45 | $12,56315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in New York
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
- Jason KindtNew York$122K
- Mahyar EidgahNew York$76K
- Anthony LyonNew York$65K
- Daniel BowersNew York$44K
- Angelina LauchangcoNew York$26K
- Orin DouglasNew York$25K
- Punyadech PhotangthamNew York$24K
- Louis BonavitaEast Syracuse$674K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.